Cabaletta Bio, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
Cabaletta Bio, Inc. announced new clinical and translational data from the first four patients in the lowest dose cohort in RESET-PV evaluating preconditioning-free rese-cel and initial...
Cabaletta Bio, Inc. announced the Appointment of Francisco Ramírez-Valle, M.D., Ph.D., to Scientific Advisory Board. Dr. Ramírez-Valle currently serves as Senior Vice President, Immunology Research...
Cabaletta Bio (CABA) remains a Buy: rese-cel trial catalysts, autoimmune upside, scalable manufacturing, and key risks like cash/dilutionâread now.
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same period last year.
Preconditioning-free 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel...
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4...
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like Cabaletta Bio Inc, Celcuity Inc, and Xerox Holdings Corp.
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
Corporate Presentation MAY 2026 © 2026 Cabaletta Bio. All rights reserved. Develop and launch the first...
Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with
PHILADELPHIA, May 04, 2026 -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients...
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 2.50M | $6.72M | 0.01% | Added+35.8% | 2026-03-31 |
| RenTech | quant | 2.04M | $5.48M | 0.01% | Added+33.8% | 2026-03-31 |
| StateStreet | passive | 470.0K | $1.26M | 0.00% | Added+10.5% | 2026-03-31 |
| Wellington | fundamental | 247.7K | $666.20K | 0.00% | New | 2026-03-31 |
| Citadel | multi-strat | 246.6K | $663.39K | 0.00% | Added+335.3% | 2026-03-31 |
| DEShaw | quant | 189.4K | $509.52K | 0.00% | New | 2026-03-31 |
| FidelityFMR | fundamental | 13.0K | $34.95K | 0.00% | Unchanged | 2026-03-31 |
| TRowePrice | fundamental | 442.3K | $1.19K | 0.00% | Trimmed-59.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.34 | — | — |
| 2026-05-14 | -0.39 | -0.39 | -0.47% |
| 2026-03-23 | -0.47 | -0.40 | +14.12% |
| 2025-11-10 | -0.46 | -0.44 | +3.88% |
| 2025-08-07 | -0.61 | -0.73 | -19.35% |
| 2025-05-15 | -0.66 | -0.71 | -7.40% |
| 2025-03-31 | -0.63 | -0.65 | -3.76% |
| 2024-11-14 | -0.61 | -0.62 | -2.17% |
| 2024-08-08 | -0.57 | -0.56 | +2.00% |
| 2024-05-15 | -0.48 | -0.51 | -5.42% |
| 2024-03-21 | -0.39 | -0.46 | -17.28% |
| 2023-11-09 | -0.42 | -0.37 | +10.96% |
| 2023-08-10 | -0.42 | -0.37 | +12.60% |
| 2023-05-11 | -0.47 | -0.45 | +4.76% |
| 2023-03-16 | -0.44 | -0.52 | -19.08% |
| 2022-11-10 | -0.47 | -0.39 | +17.02% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CABA | +28.57% | +16.31% | +72.60% | +102.14% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +25.60% | +20.95% | +76.05% | +89.45% |